Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Clinical and Economic Effectiveness of Influenza Vaccination in Older Adults

12. listopadu 2026 aktualizováno: Thong Nhat Hospital

This study aims to evaluate the clinical and economic effectiveness of influenza vaccination among adults aged 60 years and older in Ho Chi Minh City, Vietnam. It will compare influenza-related health outcomes and healthcare costs between older adults who receive influenza vaccination and those who do not.

This is a prospective observational cohort study with a control group. The study plans to enroll 2,298 participants, including 766 vaccinated and 1,532 unvaccinated older adults. Participants will be recruited at Thong Nhat Hospital and University Medical Center Ho Chi Minh City. Vaccination status will be determined by participants' vaccination history and decisions made independently of the study.

Participants will be followed for 12 months, with follow-up assessments every three months. The study will collect information on influenza, influenza-like illness, cardiovascular events, respiratory events, hospitalization, mortality, and direct medical costs related to influenza.

The study will compare the occurrence of clinical outcomes and direct medical costs between the two groups. It will also evaluate economic measures related to influenza vaccination, including avoided treatment costs, cost savings, and the benefit-cost ratio. The findings will be used to provide scientific evidence for developing influenza vaccination policy recommendations for older adults in Ho Chi Minh City.

Přehled studie

Postavení

Zatím nenabíráme

Detailní popis

Participants will be recruited using consecutive convenience sampling. Baseline information will be collected using standardized data collection forms, including demographic characteristics, medical history, underlying diseases, influenza vaccination status, and other relevant clinical information.

During follow-up, data will be collected through scheduled telephone contacts, community-based follow-up, and information obtained from healthcare facilities. Reported clinical events and healthcare utilization will be verified using available medical records and other relevant sources.

To address potential differences in baseline characteristics between the vaccinated and unvaccinated groups, the study will use statistical methods to control for confounding factors. Propensity score matching will be applied to improve comparability between the two groups. The clinical and economic effectiveness of influenza vaccination will be evaluated using the collected data.

Typ studie

Pozorovací

Zápis (Odhadovaný)

2298

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní záloha kontaktů

  • Jméno: Phan H Le, MD
  • Telefonní číslo: +84 795 974 545
  • E-mail: lhphan@ump.edu.vn

Studijní místa

    • Ho Chi Minh City
      • Ho Chi Minh City, Ho Chi Minh City, Vietnam
        • Thong Nhat Hospital
        • Kontakt:
        • Kontakt:
      • Ho Chi Minh City, Ho Chi Minh City, Vietnam
        • University Medical Center Ho Chi Minh City
        • Kontakt:
        • Kontakt:

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

60 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ano

Pohlaví způsobilá ke studiu

Všechno

Metoda odběru vzorků

Vzorek nepravděpodobnosti

Studijní populace

The study population comprises adults aged 60 years or older residing in Ho Chi Minh City, Vietnam. Participants will be recruited from two cohorts: older adults receiving one dose of influenza vaccine at the vaccination centers of Thong Nhat Hospital or University Medical Center Ho Chi Minh City at enrollment, and unvaccinated older adults attending outpatient clinics at these hospitals who have not received influenza vaccination within the preceding 12 months. Participants will be selected using consecutive convenience sampling and followed for 12 months.

Popis

Inclusion Criteria:

  • Adults aged 60 years or older residing in Ho Chi Minh City, Vietnam.

  • Belonging to one of the following two groups:

    • Vaccinated group: Older adults receiving one dose of influenza vaccine at the Vaccination Center of Thong Nhat Hospital or University Medical Center Ho Chi Minh City at the time of enrollment.
    • Unvaccinated control group: Older adults attending outpatient clinics at Thong Nhat Hospital or University Medical Center Ho Chi Minh City who have not received influenza vaccination within the preceding 12 months.
  • Having complete contact information and being able to be followed for 12 months through follow-up visits, telephone contact, and/or community-based follow-up.

  • Agreeing to participate in the study and providing written informed consent.

Exclusion Criteria:

  • Inability to accurately determine influenza vaccination status or the timing of influenza vaccination.
  • Refusal to participate in the study or withdrawal from the study during the prospective follow-up phase.
  • Participants in the unvaccinated control group who receive influenza vaccination during the 12-month follow-up period.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Observační modely: COHORT
  • Časové perspektivy: PROSPECTIVE

Kohorty a intervence

Skupina / kohorta
Intervence / Léčba
Influenza-Vaccinated Cohort

Adults aged 60 years or older who receive influenza vaccination at the vaccination centers of Thong Nhat Hospital or University Medical Center Ho Chi Minh City during the study period. The date of vaccination serves as the start of the 12-month follow-up period.

Influenza vaccination received as part of routine healthcare, independently of the study. Vaccination is not assigned or administered by the research team as a study intervention. Participants who receive influenza vaccination are included in the vaccinated cohort and followed for 12 months.

Unvaccinated Control Cohort

Adults aged 60 years or older attending outpatient clinics at Thong Nhat Hospital or University Medical Center Ho Chi Minh City who have not received influenza vaccination during the 12 months preceding enrollment. The enrollment date serves as the start of the 12-month follow-up period.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Incidence of Confirmed Influenza
Časové okno: During the 12-month follow-up period

The proportion of participants with confirmed influenza during the 12-month follow-up period. Confirmed influenza is defined by a positive rapid influenza antigen test, a positive reverse transcription-polymerase chain reaction (RT-PCR) test, viral isolation, or a documented influenza diagnosis in the medical record, in accordance with the study protocol.

During the 12-month follow-up period
Incidence of Influenza-like Illness
Časové okno: During the 12-month follow-up period

The proportion of participants experiencing influenza-like illness (ILI) during the 12-month follow-up period. ILI is defined as an acute respiratory illness characterized by fever (measured body temperature of at least 38°C or self-reported fever or chills) accompanied by cough and/or sore throat, as specified in the study protocol.

During the 12-month follow-up period
Avoided Treatment Costs
Časové okno: Over the 12-month follow-up period

The estimated total treatment costs avoided through influenza vaccination over the 12-month follow-up period. Avoided treatment costs are calculated as the difference in mean treatment costs between the unvaccinated and vaccinated groups, multiplied by the number of vaccinated participants. Costs are expressed in Vietnamese dong (VND).

Over the 12-month follow-up period
Net Cost Savings
Časové okno: Over the 12-month follow-up period

Net cost savings associated with influenza vaccination over the 12-month follow-up period, calculated as the total estimated treatment costs avoided minus the total vaccination costs, in accordance with the study protocol. Net cost savings are expressed in Vietnamese dong (VND).

Over the 12-month follow-up period
Benefit-Cost Ratio
Časové okno: Over the 12-month follow-up period

The benefit-cost ratio of influenza vaccination over the 12-month follow-up period, calculated by dividing the total estimated treatment costs avoided by the total vaccination costs, as specified in the study protocol. The benefit-cost ratio is expressed as a dimensionless ratio.

Over the 12-month follow-up period

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Incidence of Respiratory Events
Časové okno: During the 12-month follow-up period

The proportion of participants experiencing respiratory events during the 12-month follow-up period. Respiratory events include bronchitis, pneumonia, acute exacerbations of chronic obstructive pulmonary disease, and acute exacerbations of asthma, as defined in the study protocol.

During the 12-month follow-up period
Incidence of Cardiovascular Events
Časové okno: During the 12-month follow-up period

The proportion of participants experiencing cardiovascular events during the 12-month follow-up period. Cardiovascular events include acute myocardial infarction, acute stroke, and acute heart failure, as defined in the study protocol.

During the 12-month follow-up period
Incidence of Influenza-Related Hospitalization
Časové okno: During the 12-month follow-up period

The proportion of participants hospitalized during the 12-month follow-up period due to influenza, influenza-related conditions, or complications of influenza, as defined in the study protocol.

During the 12-month follow-up period
Influenza-Related Mortality
Časové okno: During the 12-month follow-up period

The proportion of participants who die during the 12-month follow-up period due to influenza, influenza-related causes, or complications of influenza, as defined in the study protocol.

During the 12-month follow-up period
Total Direct Medical Costs
Časové okno: Over the 12-month follow-up period

The total actual direct medical costs incurred during the 12-month follow-up period for the management of study-related clinical events. Costs are calculated by summing the actual medical expenditures associated with all relevant treatment episodes during follow-up and are expressed in Vietnamese dong (VND).

Over the 12-month follow-up period
Total Medical Costs Based on Health Insurance Rates
Časové okno: Over the 12-month follow-up period

The total medical costs associated with study-related clinical events during the 12-month follow-up period, calculated using the reimbursement rates specified by the Vietnamese health insurance system. Costs are summed across relevant treatment episodes and expressed in Vietnamese dong (VND).

Over the 12-month follow-up period

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Vyšetřovatelé

  • Vrchní vyšetřovatel: Tan V Nguyen, PhD, Thong Nhat Hospital

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

1. ledna 2027

Primární dokončení (Odhadovaný)

1. května 2028

Dokončení studie (Odhadovaný)

1. května 2028

Termíny zápisu do studia

První předloženo

12. listopadu 2026

První předloženo, které splnilo kritéria kontroly kvality

12. listopadu 2026

První zveřejněno (Aktuální)

18. listopadu 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

18. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

12. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • 26175-BVTN
  • 54/2026/HĐ-QKHCN (Jiné číslo grantu/financování: Ho Chi Minh City Science and Technology Development Fund)

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NEROZHODNÝ

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit